Byam Jerome, Renz John, Millis J Michael
Department of Transplantation, University of Chicago, Chicago, IL 60637, USA.
Hepatobiliary Surg Nutr. 2013 Feb;2(1):22-30. doi: 10.3978/j.issn.2304-3881.2012.11.03.
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and is considered an aggressive tumor with mean survival estimated between 6 and 20 months. Hepatitis B and C are the most common etiologies. Pathological, laboratory and radiologic imaging all aid in diagnosis but much controversy exists in the utilization of any given modality. Many treatment options exist for management of HCC, each has its own limitation. Liver transplantation offers the most reasonable expectation for curative treatment while simultaneously removing the burden of the diseased liver. Still, advancements in the field have thus far not yet matched its potential, although new immunosuppressive and chemotherapy regimen may allow transplantation to push the envelope once again.
肝细胞癌(HCC)是最常见的肝脏原发性肿瘤,被认为是一种侵袭性肿瘤,平均生存期估计在6至20个月之间。乙型和丙型肝炎是最常见的病因。病理、实验室和放射影像学检查都有助于诊断,但在任何一种特定检查方法的应用上都存在很多争议。HCC的治疗有多种选择,每种都有其局限性。肝移植为治愈性治疗提供了最合理的期望,同时消除了患病肝脏的负担。尽管如此,该领域的进展至今尚未达到其潜力,不过新的免疫抑制和化疗方案可能会使移植再次突破极限。